Position of the Transparency Council – Bellix (bilastinum)
At its meeting on 28 April 2025, the Transparency Council adopted position No. 48/2025 on the evaluation of the medicinal product Bellix (bilastinum) for the indication: symptomatic treatment of allergic rhinitis and conjunctivitis and urticaria in adults and adolescents (aged 12 years and above).